Detalhe da pesquisa
1.
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid.
Liver Int
; 42(11): 2453-2465, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35932095
2.
Interleukin-28B genetic variants in untreated Italian HCV-infected patients: a multicentre study.
Liver Int
; 35(2): 482-8, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25039676
3.
Lemierre's syndrome complicated by cerebral venous sinus thrombosis: A life threatening and rare disease successfully treated with empiric antimicrobial therapy and conservative approach.
Intractable Rare Dis Res
; 11(1): 37-39, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35261851
4.
Correction: SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.
PLoS One
; 14(9): e0223287, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31553772
5.
SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.
PLoS One
; 14(5): e0215783, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31091254
6.
HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study.
Dig Liver Dis
; 49(9): 1022-1028, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28487083
7.
Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience.
PLoS One
; 9(10): e110284, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25340799